deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02470780

Treating Bacterial Overgrowth in Parkinson's Disease (SIBO-PD)

Sponsor: University of Cincinnati

Updated 8 times since 2017 Last updated: Feb 27, 2024 Started: Dec 31, 2015 Primary completion: Aug 31, 2017 Completion: Aug 31, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Parkinson's Disease and Small Intestinal Bacterial Overgrowth, this trial is completed. The trial is conducted by University of Cincinnati and has accumulated 8 data snapshots since 2015. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshotRecruiting~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2024 · 39 months · monthly snapshotCompleted~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3PHASE2/PHASE3

  3. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Jan 2021 — Apr 2024 [monthly]

    Completed PHASE2_PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

Show 3 earlier versions
  1. Dec 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

    Status: RecruitingCompleted

  2. Feb 2017 — Dec 2017 [monthly]

    Recruiting PHASE2_PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Cincinnati
Data source: University of Cincinnati

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations